ReSeqTB Data Sharing Platform Q3-2015 Update
Provide a one-stop data source for clinically relevant genotypic and phenotypic information on Mycobacterium tuberculosis (M.tb.). Having such data reviewed and validated, and made accessible in one place would support the development of new tests that can rapidly inform appropriate therapy for TB patients.
- Serve as a single repository for the compilation, curation and validation of existing and newly created data on TB drug resistance correlations.
- Extensive database design and implementation to ensure quality and security of information, technical expertise with a track record of successful experience from the developer, and assurance that all relevant legal, patient data privacy, and intellectual property standards are met.
- User Acceptance Testing (UAT) achieved 100% test exposure three weeks early. Testing on track to achieve 100% pass rate before general availability (GA). Beta User Experience testing has begun.
- Selected ReSeqTB Platform hosting provider. Completed installation of cloud-based ReSeqTB Platform, performed security hardening and QA testing.
- Security audits of production environment by an independent party began.
- Development of a basic data report is complete. Development of custom reports is progressing on schedule.
- Using the communication document approved by the ReSeqTB Leadership Team, data outreach efforts to potential contributors have netted firm commitments from 15 of 111 potential contributors to date. Three contributors have transferred their datasets (approximately 1500 isolates).
- A “3-5-10” year sustainability plan has been developed. Four funding models have been defined. Six potential funding organizations were invited to attend the closed Union Symposium session on December 1, 2015.
- Plans are underway to incorporate the Knowledge Synthesis (KS) TBDR Database and interface into the ReSeqTB Data Platform. Finalizing the enhancements that were developed by KS with funding from FIND.
- The second expert panel face-to-face meeting convened in Geneva in July, 2015. Several key objectives were achieved including identifying pipeline validation tools, thresholds, quality control steps, and a draft process for validating mutations as markers of phenotypic resistance. A report is available of the meeting.
- Completed the unified variant pipeline specifications and provided a demonstration at the expert panel meeting in Geneva.
- Developed a communications plan to reach a greater audience for the Oct 31, 2015 product release and beyond.